Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: A phase II ITMO study

Annals of Oncology

Volumn 25, Issue 8, 2014, Pages 1597-1603

  Buzzoni, R ^a   Pusceddu, Sara ^a   Bajetta, E ^b   De Braud, F ^a   Platania, M ^a   Iannacone, C ^c   Cantore, M ^d   Mambrini, A ^d   Bertolini, A ^e   Alabiso, O ^f   Ciarlo, A ^g   Turco, C ^a   Mazzaferro, V ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Policlinico of Monza   (Italy)

^c Biostatistician LB Research srl   (Italy)

^d Medical Oncology Unit Asl 1   (Italy)

^e Medical Oncology Unit Presidio Ospedaliero Sondrio   (Italy)

^f Department of Translational Medicine   (Italy)

^g Oncology Unit   (Italy)

Author keywords

Advanced biliary tract cancer; Everolimus; mTOR

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; EVEROLIMUS; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; PLATINUM COMPLEX; RAPAMYCIN;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL RATE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOCALCEMIA; ITALY; MALE; MEDICAL PARAMETERS; MULTICENTER STUDY; NAUSEA AND VOMITING; OBJECTIVE RESPONSE RATE; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; STOMATITIS; THROMBOCYTOPENIA; TIME TO PROGRESSION; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADVANCED CANCER; ADVERSE OUTCOME; CANCER CONTROL; CANCER RECURRENCE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; TIME TO TREATMENT; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; BILIARY TRACT NEOPLASMS; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; QUALITY OF LIFE; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 84905189775     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu175     Document Type: Article

References (24)

1. Lepage C, Cottet V, Chauvenet M et al. Trends in the incidence and management of biliary tract cancer: a French population-based study. J Hepatol 2011; 54: 306-310.
2. Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist 2008; 13: 415-423.
3. Yalcin S. Diagnosis and management of cholangiocarcinomas: a comprehensive review. Hepatogastroenterology 2004; 51: 43-50.
4. Walter T, Horgan AM, McNamara M et al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 2013; 49: 329-335.
5. Lebwohl D, Anak O, Sahmoud T et al. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci 2013; 1291: 14-32.
6. Chung JY, Hong SM, Choi BY et al. The expression of phospho-AKT, phosphomTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 2009; 15: 660-667.
7. Wu Q, Kiguchi K, Kawamoto T et al. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res 2007; 67: 3794-3800.
8. Herberger B, Puhalla H, Lehnert M et al. Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 2007; 13: 4795-4799.
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
10. MedDRA-Medical Dictionary for Regulatory Activities. Reston, USA: International Federation of Pharmaceutical Manufacturers Associations (IFPMA).
11. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
13. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96: 896-902.
14. Furuse J, Okusaka T. Targeted therapy for biliary tract cancer. Cancers (Basel) 2011; 3: 2243-2254.
15. Lee S, Oh SY, Kim BG et al. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 2009; 32: 348-352.
16. Oh SY, Jeong CY, Hong SC et al. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 2011; 29: 1066-1072.
17. Sasaki T, Isayama H, Nakai Y et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2012; 30: 708-713.
18. Bhat M, Sonenberg N, Gores GJ. The mTOR pathway in hepatic malignancies. Hepatology 2013; 58: 810-818.
19. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135.
20. Heuer M, Dreger NM, Cicinnati VR et al. Tumor growth effects of rapamycin on human biliary tract cancer cells. Eur J Med Res 2012; 17: 20.
21. Pignochino Y, Sarotto I, Peraldo-Neia C et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010; 10: 631.
22. Costello BA, Qi Y, Borad MJ et al. Phase I trial of everolimus and gemcitabine for patients with solid tumors refractory to standard therapy and for a cohort of patients with cholangiocarcinoma/gallbladder cancer. J Clin Oncol 2010; 28: TPS166.
23. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormonereceptor- positive advanced breast cancer. N Engl J Med 2012; 366: 520-529.
24. Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011; 47: 1287-1298.